Emcure Pharmaceuticals IPO GMP: Check Price Band, Subscription Window, And Other Key Details
emcure pharmaceuticals ipo gmp: check price band, subscription window, and other key details
Emcure Pharmaceuticals, Indian pharmaceutical company, is set to launch its Initial Public Offering (IPO) on July 3, 2024. The IPO aims to raise Rs 1,952.03 crores, comprising a fresh issue of 0.79 crore shares worth Rs 800 crores and an offer for sale of 1.14 crore shares aggregating to Rs 1,152.03 crores.
Emcure Pharmaceuticals IPO Subscription WindowEmcure Pharmaceuticals IPO will open on July 3, 2024 and it will close on July 5, 2024.
Emcure Pharmaceuticals IPO Allotment And Listing DateThe allotment of shares is expected to be finalized on July 8, 2024, with the listing on the BSE and NSE scheduled for July 10, 2024.
Related News |
Allied Blenders and Distillers IPO Opens Today: Should You Subscribe? Check Expert Insights
Emcure Pharmaceuticals IPO Price BandThe price band for the IPO is set between Rs 960and Rs 1,008 per share.
and the minimum application size for retail investors is 14 shares, requiring an investment of Rs 14,112. Small Non-Institutional Investors (sNII) must apply for at least 15 lots (210 shares), amounting to Rs 211,680, while Big Non-Institutional Investors (bNII) must apply for a minimum of 71 lots (994 shares), totalling Rs 1,001,952.
Emcure Pharmaceuticals IPO GMPAs per multiple websites that track the grey market premium activities, the shares of Emcure Pharmaceuticals IPO are commanding a GMP in the price range of Rs 250 - Rs 260 in the unlisted market.
Emcure Pharmaceuticals, established in 1981, develops, manufactures, and markets a diverse range of pharmaceutical products globally. The company ranks 13th in domestic sales among Indian pharmaceutical firms for the period ending September 2023 and holds the 4th largest market share in its covered markets. Emcure is a market leader in gynaecology and HIV antiviral therapeutic areas as of September 2023.
The net proceeds from the IPO will be used to repay or prepay certain outstanding borrowings and for general corporate purposes.
Related News |
Lupin Stock Jumps Following Positive FDA Inspection Report And Key Executive Appointment